Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

NCCN Guidelines Insights: Bladder Cancer, Version 2.2022. Journal of the National Comprehensive Cancer Network : JNCCN Flaig, T. W., Spiess, P. E., Abern, M., Agarwal, N., Bangs, R., Boorjian, S. A., Buyyounouski, M. K., Chan, K., Chang, S., Friedlander, T., Greenberg, R. E., Guru, K. A., Herr, H. W., Hoffman-Censits, J., Kishan, A., Kundu, S., Lele, S. M., Mamtani, R., Margulis, V., Mian, O. Y., Michalski, J., Montgomery, J. S., Nandagopal, L., Pagliaro, L. C., Parikh, M., Patterson, A., Plimack, E. R., Pohar, K. S., Preston, M. A., Richards, K., Sexton, W. J., Siefker-Radtke, A. O., Tollefson, M., Tward, J., Wright, J. L., Dwyer, M. A., Cassara, C. J., Gurski, L. A. 2022; 20 (8): 866-878

Abstract

The NCCN Guidelines for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer and other urinary tract cancers (upper tract tumors, urothelial carcinoma of the prostate, primary carcinoma of the urethra). These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines regarding the treatment of non-muscle-invasive bladder cancer, including how to treat in the event of a bacillus Calmette-Guerin (BCG) shortage; new roles for immune checkpoint inhibitors in non-muscle invasive, muscle-invasive, and metastatic bladder cancer; and the addition of antibody-drug conjugates for metastatic bladder cancer.

View details for DOI 10.6004/jnccn.2022.0041

View details for PubMedID 35948037